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Summary The effect of Nicotinamide and/or treatment with Fluosol DA and Carbogen breathing on the
radiation response of 500-750 mg SCCVII and KHT tumours has been evaluated. Pretreatment with Fluosol
DA/Carbogen or Nicotinamide resulted in relatively modest enhancements of radiation damage with enhance-
ment factors of 1.1 and 1.3 being observed using an in vivo/in vitro clonogenic end-point. A combination of
Nicotinamide and Fluosol DA/Carbogen resulted in a larger enhancement factor of 1.6 over the radiation dose
ranges studied. These modification factors reflect a value close to that expected for a fully aerobic response in
this survival range. Growth delay studies in the SCCVII tumour provided similar results. Using a recently
developed fluorescence activated cell sorting technique, which utilizes the in vivo pharmacokinetic and DNA
binding properties of the bisbenzamide stain Hoechst 33342, the effect of Nicotinamide and/or Fluosol
DA/Carbogen schedules on the occurrence of acute hypoxia was assessed. The results clearly show that
Nicotinamide significantly reduces the amount of 'acute hypoxia', but has a lesser effect on 'chronic' hypoxic
cells. However, combinations of Nicotinamide and Fluosol DA/Carbogen significantly increase the response of
both 'acutely' and 'chronically hypoxic' cells. The results provide evidence that a combination ofNicotinamide
and Fluosol DA/Carbogen can provide an effective way of reoxygenating both acutely and chronically hypoxic
cells.
Overcoming the problem of radiation resistant hypoxic cells
continues to be a major focus of interest in radiation biology
and oncology (Coleman, 1988; Dische, 1989; Hirst, 1986;
Guichard, 1989; Brown, 1989). One of the most effective
ways of improving the oxygenation and radiation response of
experimental tumours is by the administration of fluorocar-
bon emulsions prior to a period of breathing high oxygen
content gases (Teicher & Rose, 1984; Song et al., 1985;
Rockwell, 1985; Song et al., 1987; Teicher & Rose, 1986;
Rockwell et al., 1986; Sasai et al., 1989; Thomas et al., 1989).
However, the enhancements of radiation response obtained
using such an approach indicate that complete elimination of
the radioresistant hypoxic cell population is not achieved.
One explanation for the residual pockets of radiobiological
hypoxia that exist in tumours during fluorocarbon/oxygen
therapy is that hypoxia in tumours does not result solely
from chronic diffusion limitations as described by Thomlin-
son and Gray (1955), but can occur from transient fluctua-
tions in microregional blood flow (Reinhold et al., 1977;
Intalglietta et al., 1977; Brown, 1979; Sutherland & Franko,
1980; Chaplin et al., 1987). If blood flow stops or blood
vessel occlusion occurs in a tumour microregion, many of the
resulting hypoxic cells are situated at a distance from a
functional vessel much greater than the estimated oxygen
diffusion distance of 50-230 microns (Thomlinson & Gray,
1955; Tannock, 1972). In such a situation, increasing the
oxygen carrying capacity of the blood would not be an
effective method of reoxygenation. There is now clear evi-
dence that radiobiological hypoxia in at least two experi-
mental tumours can result from transient fluctuations in
microregional blood flow (Chaplin et al., 1987; Chaplin et al.,
1986; Trotter et al., 1989; Chaplin et al., 1989; Minchinton et
al., 1990). If this acute hypoxia exists in human tumours, as
outlined above, it would limit the efficacy of fluorocarbon/
oxygen treatment when used in combination with radiation.
One obvious way to improve the effectiveness of therapy in
such a situation would be to combine it with a treatment
which reoxygenates 'acutely' hypoxic cells. With the recent
development of techniques which enable microregional
heterogeneity of oyxgen delivery to be evaluated, it is now
possible to identify agents which modulate the occurrence of
acute hypoxia. Studies with one particular agent, Nicotina-
mide, a compound known to increase tumour response to
radiation (Horsman et al., 1987; Horsman et al., 1988; Hors-
man et al., 1989), have indicated that its activity, at least in
part, results from its ability to reduce the occurrence of acute
hypoxia within a solid tumour (Chaplin et al., 1990).
As a consequence of this finding, we have evaluated the
effect of a strategy in which Fluosol DA and Carbogen (a
combination useful in reoxygenating chronic diffusion limited
hypoxia) is given together with Nicotinamide. Such a treat-
ment should, on the basis already outlined, provide a strat-
egy to reoxygenate both acutely and chronically hypoxic cells
within the tumour mass.
Materials and methods
Mice and tumour
SCCVII or KHT tumour cells obtained by enzyme disagg-
regation were implanted subcutaneously over the sacral re-
gion of the back in 6-9 week old female C3H/He mice
(Charles River Inc., Quebec, Canada). Tumours were used in
the size range 500-750mg for in vivo/in vitro assays and
500-550mg for growth delay studies.
Drugs
Nictonamide purchased from Sigma (St. Louis, Mo.) was
freshly prepared before each experiment. The drug was dis-
solved in sterile phosphate-buffered saline (PBS) and admini-
stered intraperitoneally (i.p.) at a dose of 1.0mgg'1.
Fluosol DA 20% produced by Green Cross Corporation
(Osaka, Japan) was supplied by Alpha Therapeutics Cor-
poration (Los Angeles, Ca.). An aliquot of the stem emulsion
was thawed prior to each experiment and physiological
osmolarity was attained by addition of annex solution. De-
tails of the composition of stem emulsion and annex solution
have been described previously (Teicher et al., 1989). The
resulting emulsion was injected intravenously (i.v.) via
the lateral tail vein at a dose of 0.01 ml g-' mouse
weight.
Irradiation procedure
Tumour localised irradiation was carried out without anaes-
thesia in a manner similar to that described previously
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(Chaplin et al., 1983) using 270 kVp X-rays at a dose rate of
2.9Gy min-'.
Carbogen breathing
Animals that were injected with Fluosol DA were placed in
their individual plexiglass/lead boxes in the irradiation set-up.
A plexiglass cover was then placed over the set-up and
clipped into place. The system was then gassed with Car-
bogen (95% 02, 5% C02) for 1 h prior and during irradia-
tion.
Preparation oftumour cell suspensions
The animals were sacrificed and tumours excised 18-20 h
after irradiation. Following excision, the tumours were
washed with PBS, chopped using crossed scalpels, and
weighed. The resulting fragments, after being washed with
PBS, were disaggregated by gentle agitation for 30 min with
an enzyme cocktail of trypsin (0.2%), DNAase (0.05%) and
collagenase (0.05%) at 37°C. The resulting cell suspension
was filtered through polyester mesh (50pm pore size), cen-
trifuged, and the cell pellet resuspended in medium. Cell
suspensions were routinely counted with the aid of a haemo-
cytometer enabling tumour cell yield to be ascertained. The
mean cell yields for tumours in this series of experiments
were 6.1 x l07g-I of tissue for the SCCVII tumours and
1.1 x 108 g- of tissue for the KHT tumours.
Measurement ofcell survival
Tumour cell viability was assessed using the soft agar clono-
genic assay described previously (Courtenay, 1976). Known
numbers of tumour cells were plated into soft agar and
cultured in a water saturated atmosphere of 5% 02, 5% CO2
and 90% N2 for 14 days. Tumour colonies of more than 50
cells were counted with the aid of a microscope. For the
present series of experiments, the plating efficiency for un-
treated tumours ranged between 0.29 and 0.43 for the
SCCVII, and between 0.51 and 0.82 for the KHT. The effect
of treatment on cell survival was expressed as the fraction of
surviving cells per tumour, that is:
Fraction of surviving cells/tumour
= S F xcell yield/g treated
cell yield/g untreated
We have chosen to analyse the cell survival data in terms
of enhancement factors at a given dose of radiation. En-
hancement ratios calculated from slope changes would not be
appropriate for comparing strategies which may actually be
improving oxygenation of the tumour. The effect of such
therapies would be a downward displacement of the terminal
portion of the survival curve with no change in slope. In
addition, since Nicotinamide does show a modest ability to
enhance radiation damage in vitro, presumably through some
repair inhibition process, a simple calculation of the hypoxic
fraction from a downward shift of the survival curve would
also not provide a suitable analysis.
Enhancement factors were derived from the data by com-
paring the best fit regression lines through the data. From
these lines the radiation dose required without pretreatment
to give the same survival level as 12 Gy with drug pretreat-
ment was obtained. The ratio of these doses is designated as
the enhancement factors at 12 Gy i.e. EF (12). Since the
derivation is not statistically vigorous we have, in addition to
EF (12) values, calculated the statistical significance of
differences in cell survival seen in drug pretreated and in
X-ray only groups using two tailed t-tests.
Fluorescence activated cell sorting studies
Details of the sorting procedures have been described in
detail previously (Chaplin et al., 1987). A brief description is
given here. The fluorescent bisbenzamide stain Hoechst 33342
(10 ig g-') was injected intravenously via the lateral tail vein
20 min prior to irradiation. For animals being gassed with
Carbogen, injection was achieved via an indwelling catheter.
Immediately after irradiation tumours were excised, washed
in cold PBS, chopped on ice and disaggregated. Cells were
sorted into two fractions, each representing 10% of the total
cell population, one containing the brightest cells and one
containing the dimmest cells.
Growth delay studies
Growth delay was determined using groups of 6-8 mice
bearing subcutaneous SCCVII tumours. Tumour volumes
were calculated from three orthogonal diameters. Measure-
ments were made just prior to treatment and then subse-
quently three times a week. The time taken for the individual
tumours in each treatment group to reach twice their original
volume was determined. Thus, the mean and standard error
of the time for each dose group could be calculated. For each
radiation dose group the statistical significance of growth
delay values of drug pretreated compared to X-ray only
groups was assessed using two tailed t-tests.
Results
The effect of Nicotinamide administered at a dose of
1.0 mg g-' 60 min before various doses of X-rays on tumour
cell survival can be seen in Figure 1. Nicotinamide
significantly increases radiation response at all radiation dose
levels, with an EF (12) of 1.3 being evident. From the same
figure it can be seen that administering Fluosol DA and
breathing Carbogen for 60 min prior to and during irradia-
tion results in an increased radiation response with an EF
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Figure 1 The effect of Nicotinamide or Fluosol DA and Car-
bogen on the radiation dose response as measured by an in
vivo/in vitro survival assay. C3H mice bearing 500-750 mg
SCCVII tumours were given: a, Nicotinamide (1000 mg kg- i.p.)
1 h prior to irradiation with various X-ray doses: 0 X-ray alone;
0 X-ray + Nicotinamide. b, Fluosol DA i.v. 1 h prior to irradia-
tion plus breathing Carbogen for I h prior and during irradia-
tion. 0 X-ray alone; A X-ray + Fluosol DA/Carbogen. Results
show means (± s.e.) from 3-5 treatment groups. Lines were
fitted by regression analysis. The symbol * denotes survival values
significantly different from X-ray alone (i.e. P is less than 0.05
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(12) of 1.1 being evident. However, in this series of experi-
ments the enhanced cell killing induced by pretreatment with
Fluosol DA/Carbogen did not attain significance at any dose
level. The effect of combining Nicotinamide and Fluosol
DA/Carbogen treatment on radiation response is shown in
Figure 2. It can clearly be seen from this figure that the
enhancement of radiation response is larger than that seen
with either modality alone and results in an EF (12) of 1.6.
Indeed, over the radiation dose range studied the response
observed is similar to that obtained for SCCVII cells irrad-
iated under aerobic conditions in vitro (Chaplin, unpublished
studies). The cell survival studies performed were com-
plemented with growth delay studies which are shown in
Figure 3. The results obtained show that Nicotinamide and
Fluosol DA enhance the amount of growth delay seen when
administered before irradiation consistent with the cell sur-
vival work. However, combination of the two modalities
results in a greater enhancement of radiation response and is
consistent with a dose modification factor of between 1.5 and
2.0.
Subsequent to these studies we extended our investigation
to evaluate the effects of Nicotinamide and/or Fluosol DA/
Carbogen on the radiation response of the KHT sarcoma.
These studies were initiated by the finding that KHT tu-
mours implanted subcutaneously exhibit similar microre-
gional heterogeneity of oxygen delivery as that seen in the
SCCVII tumour (Chaplin et al., 1989; Minchinton et al.,
1990). The effect of Nicotinamide administered i.p. at a dose
of 1.0 mgg-' 60 min prior to various doses of X-rays is
shown in Figure 4. It can be seen that Nicotinamide en-
hances radiation response, with an EF (12) of 1.3 being
evident. A somewhat smaller effect is seen when Fluosol
DA/Carbogen pretreatment is given, as can be seen from the
cell survival studies shown in Figure 4. Indeed, the enhance-
1o-'r
ment of radiation induced cell killing does not attain
significance at the dose level used (P is greater than 0.05) for
either agent. The effect of combining Nicotinamide and the
Fluosol DA/Carbogen pretreatments on radiation response
of the KHT sarcoma is shown in Figure 4. As with the
SCCVII there is a clear indication that combining the two
modalities results in a greater enhancement of tumour res-
ponse. The EF (12) obtained from the data shown is 1.6.
In order to further investigate the mechanism of action of
Nicotinamide and Fluosol DA in the KHT sarcoma, we have
assessed the efficacy of Nicotinamide and/or Fluosol DA on
the response of acutely hypoxic cells using a recently des-
--a 50
0
a 40
E
= 30
20
CF)
, 20
0
E
' 10
**I
/ +
0 -----'
10 20
Radiation dose (Gray)
30
Figure 3 Growth delay induced in 500-550 mg SCCVII
tumours by 0 radiation alone; * Nicotinamide 1000 mg kg-'
i.p. I h prior to irradiation; A Fluosol DA 20% plus Carbogen
breathing I h prior to and during irradiation; * Nicotinamide,
Fluosol DA and Carbogen prior to irradiation. Results show
means (± s.e.) from 6-8 animals. The symbol * denotes growth
delay values significantly different from X-ray only value (i.e. P is
less than 0.05). The symbol ** denotes growth delay values
significantly greater than Nicotinamide + X-ray group (i.e. P is
less than 0.05).
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Figure 2 The effect of Nicotinamide, Fluosol DA and Carbogen
breathing on the radiation dose response as measured by in
vivolin vitro survival. C3H mice bearing 500-750 mg SCCVII
tumours were given Nicotinamide (1000mgkg-'i.p.), Fluosol
DA. 20% (0.25ml i.v.) then placed in an atmosphere of Car-
bogen for 1 h prior to and during irradiation. 0 X-ray alone; M
X-ray + Nicotinamide/Fluosol DA/Carbogen. Results show
means (± s.e.) from 3-5 treatment groups. Lines were fitted by
regression analysis. The symbol ** denotes survival values
significantly different from Nicotinamide + X-rays (i.e. P is less
than 0.05 using two tailed t-test).
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Figure 4 The effect of Nicotinamide and/or Fluosol DA and
Carbogen on the radiation dose response as measured by an in
vivo/in vitro survival assay. C3H mice bearing 500-750 mg KHT
tumours were given: (X) - radiation alone. (N + X) - Nicotina-
mide (1000mg kg-' i.p.) I h prior to irradiation with 12 Gy of
X-rays. (FC + X) - Fluosol DA i.v. I h prior to irradiation plus
breathing Carbogen for I h prior and during irradiation.
(N + FC + X) - Nicotinamide (1000 mg kg-' i.p.), Fluosol DA.
20% (0.25 ml i.v.) then placed in an atmosphere of Carbogen for
1 h prior to and during irradiation. Results show means (± s.e.)
from 3-5 treatment groups. The symbol ** denotes survival
values significantly different from Nicotinamide + X-rays.
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cribed cell sorting technique. For these studies, Nicotinamide
and Fluosol DA were administered in a manner identical to
the other protocols, however, 20 min prior to irradiation
Hoechst 33342 was injected via an indwelling catheter into
the lateral tail vein. After excision and disaggregation the
cells were sorted and survival assessed using an in vitro
clonogenic assay. Results obtained are shown in Figure 5. In
the absence of pretreatment it can be seen that the cells
brightly stained with Hoechst show a radiation response
above that expected for completely aerobic cells (i.e.
5 x 10-4). This has been attributed to the fact that some
vessels open at the time of injection close during irradiation
resulting in a proportion of cells with a hypoxic response
(Chaplin et al., 1987; Chaplin et al., 1986; Minchinton et al.,
1990). Nicotinamide administered 60min prior to radiation
preferentially increases the response of the bright fraction.
Fluosol DA plus Carbogen breathing produces a small but
not significant increase in the response of both bright and
dim fractions with little preference for either subpopulation.
Combining Nicotinamide, Fluosol DA and Carbogen
breathing greatly increases the response of both brightly and
dimly staining subpopulations with survival levels approa-
ching that for a totally aerobic response obtained in vitro.
Discussion
The results obtained indicate that Nicotinamide and Fluosol
DA/Carbogen are both able to sensitise the hypoxic cell
compartment of SCCVII and KHT tumours to irradiaton.
However, in this study the level of increased radiation
induced killing produced by Fluosol DA/Carbogen did not
attain statistical significance (i.e. P is greater than 0.05) in
either tumour model. The EF (I2)'s of approximately 1.1 -1.3
obtained with either modality alone are consistent with much
of the previously reported data using these agents in other
tumour systems (Teicher & Rose, 1984; Rockwell, 1985;
Rockwell et al., 1986; Sasai et al., 1989; Horsman et al.,
1987; Horsman et al., 1988; Horsman et al., 1989; Chaplin et
al., 1990). However, somewhat greater enhancements of
radiation effects by Fluosol DA/Carbogen treatment have
been reported in some systems (Song et al., 1985; Song et al.,
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Figure 5 The response of KHT tumour cells as a function of
fluorescence intensity after i.v. bolus of Hoechst 33342 given
20 min prior to 12 Gy of X-rays. (X) - rays alone; (N + X) -
Nicotinamide (1000mg kg-' i.p.) 1 h prior to irradiation;
(FC + X) - Fluosol DA (0.25 ml i.v.) I h prior to irradiation, and
Carbogen breathing I h prior to and during irradiation;
(N + FC + X) - Nicotinamide, Fluosol DA and Carbogen before
irradiation. Fraction B is the brightest 10% of tumour cells.
Fraction D is the dimmest 10% of the tumour cells. Results show
means (± I s.e.) from 3-8 tumours. The arrow indicates the
survival of the unsorted population ('all sort'). The symbol *
denotes survival values significantly different from that obtained
for X-ray alone for the given fluorescence fraction. The symbol
** denotes survival values significantly different from that
obtained for Nicotinamide + X-rays.
1987; Teicher & Rose, 1986). As alluded to in the introduc-
tion, the results obtained previously could be explained by
each agent having its predominant effect on either the chron-
ically or acutely hypoxic cell compartment.
There is evidence that in the two tumour systems used in
the present study hypoxia can result at least in part from
dynamic fluctuations in microregional blood flow (Chaplin et
al., 1987; Chaplin et al., 1986; Trotter et al., 1989, Chaplin et
al., 1989; Minchinton et al.,- 1990). Furthermore, recent
studies have shown that prior treatment of tumour bearing
animals with Nicotinamide can reduce the amount of acute
hypoxia occurring in the SCCVII tumour (Chaplin et al.,
1990). This finding is consistent with previous reports indi-
cating that Nicotinamide can result in an increase in tumour
perfusion and reduction in the amount of hypoxia (Horsman
et al., 1988; Horsman et al., 1989). In contrast to this action
of Nicotinamide, it would be expected that Fluosol DA/
Carbogen breathing would result in an increase in the oxygen
carrying capacity of blood and thus would not be effective at
reoxygenating areas in which blood flow was temporarily
stopped or blood vessels occluded i.e. 'acute hypoxia'. In-
direct support for this stems from a recent study by Teicher
et al. (1989) which indicates that chemical radiation sen-
sitisers such as misonidazole, which should sensitise both
acutely and chronically hypoxic cell populations (Chaplin et
al., 1986), enhance the effect of Fluosol DA on radiation
response of the FSallC fibrosarcoma.
The strategy behind the present study was to combine a
modality which would increase the oxygen carrying capacity
of the blood [Fluosol DA/Carbogen] with one which would
reduce the dynamic changes in microregional oxygen delivery
[Nicotinamide] with the overall aim of reoxygenating both
chronically and acutely hypoxic cells. The EF (12) obtained
with either agent alone was relatively modest i.e., 1.3. How-
ever, the results provide clear evidence that if the two
modalities are combined, the enhancement of radiation res-
ponse is increased (EF (12) = 1.6). This finding would be
consistent with the reoxygenation of both acutely and chron-
ically hypoxic cells. Further evidence supporting this hypo-
thesis is obtained from the sorting data shown in Figure 5. In
this protocol the hypoxic response of brightly staining cells is
due to vessels which close down between Hoechst injection
and irradiation. The hypoxic response of the dimly staining
cells probably represents classic 'Thomlinson and Gray'
diffusion limited hypoxia, with some contribution from cells
in areas where vessels are closed down for a period exceeding
the time between Hoechst 33342 injection and irradiation. It
can be seen that Nicotinamide has a large sensitising effect
on the brightly staining cell population and a more modest
effect on the dimly staining population. These results are
similar to those recently obtained in the SCCVII tumour and
are consistent with a reduction in acute hypoxia. The effect
on the dimly staining population is difficult to interpret since
it could simply reflect opening of vessels which are occluded
for a period exceeding 20 min or an effect on diffusion
limited hypoxia, for example, by increased oxygen delivery.
Fluosol DA plus Carbogen breathing produces a small but
not significant increase in the response of both brightly and
dimly stained cells. The result would suggest that Fluosol DA
is not as effective as Nicotinamide in reducing acute hypoxia.
However, the observation that a small amount of sensitisa-
tion may occur could indicate that some vessels are not
totally occluded and that the Fluosol DA emulsion can
reoxygenate these areas from which erythrocytes are excluded
because of their size. This interpretation could also explain
the results recently obtained by Holden et al. (1990) who,
using a similar sorting technique in which the Hoechst was
injected 24 h post irradiation, noted that Fluosol DA/Car-
bogen administration prior to irradiation sensitises both
brightly and dimly staining cell populations.
Combining Nicotinamide, Fluosol DA and Carbogen as
shown in Figure 5 has a marked sensitising effect on both
bright and dim cell subpopulations, indeed, from the results
shown it would appear that at this radiation dose little or no
hypoxic response can be detected in either subpopulation. It
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is an appealing assumption that combining an agent which
modifies dynamic microregional fluctuation in oxygen de-
livery (Nicotinamide) with one that increases the oxygen
delivery capacity of the blood (Fluosol DA/Carbogen) pro-
vides a complementary schedule for overcoming the 'acute'
and 'chronic' hypoxia known to exist in certain tumours.
Further detailed work in other tumour systems and in nor-
mal tissues is now required to further test the efficacy of this
combination. The contribution of repair inhibition properties
of Nicotinamide (Jonsson et al., 1985; Kjellen et al., 1986)
has not been investigated in the present study. Although
previous reports have indicated that such effects may be
minimal in experimental tumours in vivo (Horsman et al.,
1989), further work is needed in this area, particularly in
fractionated treatment schedules. Indeed, the combination of
repair inhibition and increased tumour oxygenation would
provide a double-edged sword for use in fractionated radio-
therapy.
In conclusion, the present study indicates that the com-
bination of Nicotinamide, Fluosol DA and Carbogen pro-
vides an effective strategy for increasing radioresponsiveness
of hypoxic cells in vivo. Evidence is provided that one of the
mechanisms responsible for this effect is a reduction of acute
and chronic hypoxia within the tumour mass.
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